Avant View

When Drug Delivery Becomes the Innovation – What the $2.1B Novo Nordisk–Vivtex deal signals about the future of medicines

With insights from Dr. Christine Allen, Co-Founder & CEO, Intrepid Labs

The recent partnership between Novo Nordisk and Vivtex, potentially worth up to $2.1 billion, is another signal that the future of medicine will not be defined solely by the active pharmaceutical ingredient. Increasingly, how a therapy is delivered may be just as important as the therapy itself.

The deal centers on Vivtex’s technology for improving oral delivery of peptide drugs, including GLP-1 therapies used to treat obesity and metabolic disease. While these medicines have reshaped the therapeutic landscape, most still require injections creating barriers to adherence, accessibility, and global scalability. Making these therapies easier to take could dramatically expand their reach.

For us at AVANT BIO, this development reinforces a core investment thesis: therapeutic breakthroughs increasingly depend on enabling technologies – the tools, platforms, and systems that make new modalities practical for patients and scalable for the healthcare system.

The next frontier: beyond SNAC

Today, the only widely used oral delivery technology for GLP-1 drugs relies on a molecule called SNAC, which helps peptides survive the stomach environment and enter the bloodstream. The Novo Nordisk–Vivtex partnership reflects a growing recognition that new delivery platforms will be required to unlock the full potential of peptide and biologic medicines.

As Dr. Christine Allen, co-founder and CEO of Intrepid Labs, explains:

“Novo Nordisk’s newly announced partnership with Vivtex underscores a broader shift we’ve been watching. Delivery technology is increasingly recognized as a primary value driver, especially as the industry races to make next-generation metabolic medicines easier to take and easier to scale.”

The rise of delivery platforms

Rather than optimizing one drug at a time, companies are building technologies that can systematically improve the delivery of many therapeutics across modalities and indications. That shift is beginning to reshape how both pharmaceutical companies and investors think about where long-term value will be created.

Dr. Allen notes, “This kind of partnership validates the growing role of specialist investors backing drug-delivery innovation. The winners won’t be defined only by the active pharmaceutical ingredient, but by the enabling formulation that makes the therapy clinically viable and commercially adoptable.”

One of the companies pushing this platform approach further is Intrepid Labs, an AVANT BIO portfolio company. Intrepid applies a design-make-test-learn model, integrating automation, real-time analytics, and AI-guided formulation design to accelerate the development of patient-friendly drug products. Intrepid’s approach aims to broadly transform how formulations are designed.

As Dr. Allen describes it:

“Vivtex is a platform company built around an ex vivo screening system that uses porcine GI tissue to approximate how drugs might behave in the human gut and guide improvements in oral absorption. Intrepid applies that platform mindset across formulation more broadly, using AI-guided, automated design-make-test-learn cycles and real-time analytics to turn more therapeutics into patient-centric products.”

Why this matters

For patients, the implications are straightforward. Better delivery technologies can mean:

  • Oral alternatives to injectable therapies
  • Improved convenience and adherence
  • Lower manufacturing and distribution complexity
  • Greater global accessibility

For the life sciences ecosystem, the message is equally clear. The future of medicine will depend on the technologies that enable therapies to reach patients effectively. The Novo Nordisk–Vivtex partnership is another reminder that some of the most valuable innovation in biotech happens behind the scenes – in the platforms that make breakthrough medicines possible.

At AVANT BIO, this is exactly where we see opportunity.

Follow Intrepid Labs LinkedIn, and visit their website to learn more about their technology